Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(33%)
Results Posted
33%(1 trials)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_2
1
17%
Ph phase_4
2
33%
Ph phase_3
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Active, not recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 31 (20.0%)
Phase 42 (40.0%)
N/A1 (20.0%)

Trials by Status

completed350%
active_not_recruiting233%
withdrawn117%

Recent Activity

2 active trials
Showing 5 of 6
active_not_recruitingphase_2

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

NCT01984138
active_not_recruitingphase_4

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

NCT06353269
completed

Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy

NCT05243823
completedphase_3

The Vaginal Health Trial

NCT02516202
withdrawnphase_4

Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery

NCT02860897
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01984138Phase 2

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

Active Not Recruiting
NCT06353269Phase 4

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

Active Not Recruiting
NCT05243823

Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy

Completed
NCT02516202Phase 3

The Vaginal Health Trial

Completed
NCT02860897Phase 4

Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery

Withdrawn
NCT02528383Not Applicable

Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6